Searched for
NYSTATIN
Alembic Pharmaceuticals' JV gets USFDA final nod for anti-fungal drugThe approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Nystatin and Triamcinolone...- Pharma stocks crash after US lawsuit over price manipulationsThe other generic makers named in the suit include Apotex, Teva, Heritage Pharma and Par Pharma.
- Zydus Cadila gets USFDA nod for anti-fungal ointmentThe group has more than 226 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs) since it started filings in 2003...
- Stocks in the news: DMart, IndusInd Bank, ONGC and Dr Reddy’s LabsHere's a look at the top stocks that may hog the limelight in today's session:
- Stocks in focus on June 5, 2018Here is a list of stocks that are likely to be in focus in today's trading session.
- Zydus Cadila gets USFDA nod for skin ointment, stomach ailment drugZydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Nystatin Ointment USP, 1...
- Top stocks in focus on Monday, 12 June 2017Weak signals from global markets and some key data releases may chart market direction.
- Dr Reddy's launches anti-fungal ointment in the USDr Reddy's Laboratories' shares today were trading at Rs 3,178.70 in the morning trade on the BSE, down 0.03 per cent.
- Glenmark Pharma gets USFDA nod for anti-fungal ointmentGlenmark Pharmaceuticals USA has been granted final approval by the US Food & Drug Administration (USFDA) for the "nystatin and triamcinolo...
- Glenmark gets USFDA final nod for anti-fungal ointmentGlenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (USFDA) for nystatin and triamcinolone ...
- Dr. Reddy’s & Sun Pharma to see strong Q3 earnings growth: Arvind Bothra, Religare"Lupin would have a stable revenue growth merely because some of the recent launches that they have had have been in the latter part of the...
- Dealing room buzz: Sun Pharma, RInfra, Ranbaxy and BhartiET Now spoke to dealers on institutional and HNI's activity in the dealing room. These stocks were on their radar on unconfirmed reports.
- Sun Pharma gains as subsidiary Taro inks drug pactElara Capital is of the view that current valuations of the company are rich and has maintained its ‘accumulate’ rating with target price o...
Load More
